Outcome of Board Meeting dtd. 07.08.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended 30 June 2025). Standalone revenue from operations surged to Rs 1,037.71 lakh from Rs 272.19 lakh a year ago, while consolidated revenue from operations rose to Rs 1,625.87 lakh from Rs 955.78 lakh. Despite the sharp revenue growth, standalone profit after tax fell to Rs 32.49 lakh from Rs 41.37 lakh and consolidated PAT declined to Rs 49.10 lakh from Rs 60.15 lakh, reflecting heavy cost expansion in employee benefits and other expenses. The statutory auditor (R.A. Kuvadia & Co.) issued an unqualified limited review report on both sets of results. The board also noted the allotment of 23,000 ESOPs and the shareholders' approval on 4 July 2025 for issuing 2,41,000 convertible warrants on a preferential basis to promoter group entity Aura Alkalies and Chemicals Pvt Ltd.
Strong top-line growth on a low base is positive, but simultaneous sharp drop in profitability signals margin pressure that investors should monitor closely. The promoter-group preferential warrant issue and ESOP grant are mild dilutive but supportive of long-term capital and talent.